Summary
This analysis, published in Nature Mental Health, synthesises available pre-clinical, mechanistic, and clinical evidence on the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) — medications approved for diabetes and obesity — on cognitive and psychiatric conditions. The authors evaluate the potential for repurposing these agents in neurological and mental health disorders, while also critically appraising concerns about their neuropsychiatric safety profile. The paper provides a structured evidence base to inform both future research priorities and clinical decision-making regarding GLP-1RA use in populations with or at risk of mental health conditions.
UK applicability
The findings are broadly applicable to UK clinical practice and policy, given NHS prescribing of GLP-1RAs (e.g. semaglutide, liraglutide) for type 2 diabetes and obesity, and growing interest from NICE and NHS England in their wider therapeutic potential. UK clinicians and commissioners considering GLP-1RA use in patients with comorbid mental health conditions would benefit from the safety and efficacy evidence synthesised here.
Key measures
Number of pre-clinical and mechanistic studies reviewed (278); number of clinical studies reviewed (96); neuropsychiatric outcomes across cognitive and mental health disorder categories; safety and adverse event data
Outcomes reported
The study examined the effects of GLP-1 receptor agonists across a range of neurological and psychiatric conditions, drawing on pre-clinical, mechanistic, and clinical evidence. It assessed both the therapeutic repurposing potential and the neuropsychiatric safety profile of these agents.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.